Navigation Links
Takeda Enters Into Global Strategic Partnerships With Covance and Quintiles
Date:2/15/2011

DEERFIELD, Ill., Feb. 15, 2011 /PRNewswire/ -- Takeda Pharmaceuticals International, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, today announced that its Pharmaceutical Development Division has entered into strategic partnerships with Covance (NYSE: CVD) and Quintiles, two of the world's largest full-service contract research organizations.

Under terms of the agreements, Covance and Quintiles will work in close partnership with Takeda to plan and execute global development programs to support new compounds in all therapeutic areas, except oncology. Takeda will have access to the clinical development capabilities and central laboratory services of Covance and Quintiles, with each partner company providing dedicated resources to support Takeda's development pipeline. Takeda intends to use a global program-level sourcing strategy to increase operational efficiency. Through these relationships, Takeda will move toward a fully virtual outsourcing model combining the expertise and capabilities of Takeda with those of Covance and Quintiles to improve productivity and facilitate Takeda's global growth.  

"Takeda is focused on growing its global drug development footprint, especially in Asia, while at the same time ensuring quality and increasing efficiency of our operations," said Robert Ahlbrandt, Ph.D., senior vice president, global development operations for Takeda's Pharmaceutical Development Division. "Our new strategic partnerships with Covance and Quintiles will improve the agility and productivity of our drug development activities, helping us to deliver innovative new medicines to patients globally."

About Takeda Pharmaceuticals International, Inc.

Located in Deerfield, Illinois, Takeda Pharmaceuticals International, Inc. is a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, an industry leader and the largest pharmaceutical company in Japan. Takeda Pharmaceuticals International, Inc. is the hub for R&D excellence and the commercial activities in Americas and Europe as well as other strategic functions of Takeda group. It is committed to maximize the global market potential of new products and the company's international presence to realize Takeda's Mission to strive toward better health for patients through leading innovation in medicine. Additional information about Takeda is available through its corporate Web site, www.takeda.com.


'/>"/>
SOURCE Takeda Pharmaceuticals International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Takeda Completes Settlements With All Defendants in U.S. Patent Litigation Involving ACTOS® (pioglitazone HCI), ACTOplus met® (pioglitazone HCl and metformin HCl) and duetact® (pioglitazone HCl and glimepiride)
2. Takeda Responds to Announcement about Suspension of Rosiglitazone Marketing Authorization in Europe and Restrictions in the U.S.
3. Arthritis Foundation and Takeda Launch First-Ever National Gout Public Service Announcement (PSA) Campaign, Urging People Living With Gout to Keep Enjoying Lifes Simple Pleasures
4. Orexigen® Therapeutics and Takeda Enter Into Partnership to Commercialize Contrave® in North America
5. Takeda Responds to FDA Advisory Committee Recommendation
6. Takeda Provides Update on Patent Litigation for ACTOS(R) (pioglitazone HCl) and ACTOplus met(R) (pioglitazone HCl and metformin HCl) in the U.S.
7. CellCentric Licenses Novel Epigenetic Discovery Programme to Takeda
8. Amylin and Takeda Announce Decision to Advance Development of Pramlintide/Metreleptin Combination Treatment for Obesity
9. Takeda Announces Initiation of Trial to Study the Concomitant Use of Dexlansoprazole and Other Proton Pump Inhibitors with Plavix(R) (clopidogrel bisulfate)
10. Emerging Agents from Theravance/Astellas, Johnson & Johnson/Basilea and Forest/Astrazeneca/Takeda Will Drive Modest Growth in the MRSA Drug Market Through 2018
11. Takeda San Francisco, Inc. Appoints Michael Buckley, Ph.D. Vice President of Process Sciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... , Oct. 12, 2017 AVACEN Medical ... the company with their  2017 New Product Innovation Award ... on extensive primary and secondary medical device market research by ... through its first-to-market OTC, drug-free pain relief product, the AVACEN ... approach to treating fibromyalgia widespread pain. ...
(Date:10/11/2017)... Oct. 11, 2017  True Health, a leader ... its effort during National Breast Cancer Awareness month ... risks. Research ... calculated that more than 10 million American women ... in BRCA1 or BRCA2 and have not had testing. ...
(Date:10/5/2017)... Oct. 5, 2017  In response to the ... and Maxillofacial Surgeons (AAOMS) released prescribing recommendations that ... be used as a first-line therapy to manage ... Recognizing the value and ... Paper "Opioid Prescribing: Acute and Postoperative Pain Management" ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... The International Association of Eating ... excellence for the field of eating disorders, announces the opening of early registration ... Orlando, Florida at the Omni Resort at ChampionsGate. , The annual ...
(Date:10/13/2017)... LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for care ... is the 90-day elimination period, when the family pays for care, is often waived, ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... will be giving viewers the lowdown on sciatica in a new episode of ... that focuses on current events and innovation and investigates each subject in-depth with ...
(Date:10/12/2017)... ... 12, 2017 , ... CitiDent and San Francisco dentists, Dr. ... Oventus O2Vent technology. As many as 18 million Americans are estimated to suffer ... Oral appliances can offer significant relief to about 75 percent of people with ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... AccentCare, a leader in post-acute health care, have expanded their existing home health ... Home Health. , AccentCare has been operating a joint venture home health company ...
Breaking Medicine News(10 mins):